It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Our deep expertise in target biology, therapeutic areas and collaborative workflows ensure efficient design and implementation of high-quality assays that accelerate your programs. From target validation and hit finding to building robust cascades and exploratory biology, our track record speaks for itself. We advance projects from hit identification to candidate nomination.
At Sygnature Discovery, we accelerate your drug discovery projects with tailored bioscience solutions that integrate seamlessly into your research.
Our scientists work closely with your team to design robust assays and cascades, generate reliable data, and overcome complex biological challenges, so your projects move forward with confidence.
By combining advanced technologies with collaborative problem-solving, we deliver accurate, reproducible results that enable smarter decisions across the discovery pipeline. Acting as an extension of your team, we provide both technical expertise and strategic insight to give your program the best chance of success.
What We Offer
Design and execute reliable, relevant screening cascades to support project progression
Provide flexible solutions and recommendations tailored to your needs
Screen novel compounds for project-specific properties, including cellular function and isolated target engagement
Apply the latest technologies and techniques to reduce risk later in the pipeline.
Deliver adaptable capabilities across therapeutic areas and modalities to help you reach your goals
Our Bioscience Capabilities
Our highly qualified specialist teams deliver exceptional service through standalone, execution-only, or fully integrated support models.
Cell Line Generation
Custom stable cell lines with robust expression and assay reproducibility, streamlined design and validation for confident drug discovery workflows.
Custom assay solutions built around your biology delivering reliable, decision-ready data to advance hit finding and compound profiling with confidence.
Precise ion channel and transporter insights through tailored electrophysiology studies supporting target validation, hit identification, and lead optimization decisions.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
Tailored cell-based assays for target validation, compound profiling, and mechanism studies delivering robust, physiologically relevant data to guide discovery.
Custom biochemical assays built around your target biology providing robust, high-quality data to guide hit identification and mechanism-of-action studies.
High-throughput biophysical solutions for binding, kinetics, and target engagement combining advanced technologies with deep expertise to guide drug discovery.
We combine comprehensive capabilities with state-of-the-are instrumentation to deliver solutions across diverse projects and pipelines. Our flexible engagements models adapt as your needs evolve.
Personalized Programs
Custom assay design or transfer, with data interpretation and problem-solving support.
Robust Cascade Design & Execution
Routine screening schedules provide rapid, decision-ready data with tracked assay statistics for consistency.
Transparent Communication
Regular team meetings and updates tailored to your requirements.
Flexible Working Models
Scalable services for integrated or standalone support, delivered on time and within budget.
Data Security
ISO27001 -compliant systems for secure date sharing and reporting.
Technology and Insight Access
Cutting-edge equipment and methodologies without capital investment, plus insights into competitive landscapes and emerging opportunities.
Why Choose Sygnature Discovery for Bioscience Support?
Our Bioscience department is part of our integrated drug discovery team, enhancing your project at any stage of the pipeline. You’ll have direct access to bench scientists who collaborate to address your scientific needs, ensuring your program has the best chance of success.
Our cross-trained scientists bring expertise across multiple disciplines, supported by experienced leaders who uphold the highest standard of development and data integrity. Whether you need standalone assay support or a comprehensive cascade, we provide solutions tailored to your goals.
Meet our Team
Learn more about the experts with deep expertise in target biology and therapeutic areas. Meaning faster, smarter decisions for your project.
Sygnature Discovery is attending SLAS2026 in Boston. Meet our Bioscience, DMPK and Physical Sciences experts as they share practical insight across early discovery and lead pre‑clinical drug discovery workshops onsite.
